Kymriah becomes first CAR T available on NHS England
Novartis AG (NYSE:NVS; SIX:NOVN) said it has reached an agreement with NHS England to make Kymriah tisagenlecleucel available in England, which the agency said marks Europe's first full access deal for a CAR T therapy.
NHS access to Kymriah is limited to patients under 25 years old with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant or in second or later relapse...
BCIQ Company Profiles
BCIQ Target Profiles